查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654350

靜脈免疫球蛋白市場規模、佔有率、趨勢分析報告：按應用、通路、地區、細分市場預測，2025-2030 年

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 153 Pages | 商品交期: 2-10個工作天內

價格

靜脈注射免疫球蛋白市場的成長和趨勢

根據 Grand View Research, Inc. 的一份新報告，全球靜脈注射免疫球蛋白市場規模預計將到 2030 年達到 210.5 億美元，2025 年至 2030 年期間的複合年成長率為 7.2%。

在預計預測期內，免疫不全症盛行率的增加和靜脈注射免疫球蛋白療法的採用將推動市場成長。此外，免疫球蛋白的仿單標示外使用增加以及醫療領域的投資正在推動市場成長。此外，出血性疾病的增加和老齡人口的成長也是推動該行業成長的因素。

預計皮下免疫球蛋白在治療原發性免疫力缺乏和替代療法中的應用將越來越廣泛，這將成為未來七年市場成長的基礎。此外，主要市場參與企業正專注於推出創新產品以擴大其全球分銷網路。例如，Octapharma US 於 2021 年 7 月獲得 FDA 批准，推出該公司首個靜脈注射免疫球蛋白產品 Octagam 10%，該產品推薦用於治療成人免疫介導的發炎性疾病—皮肌炎。

目前，COVID-19 疫情已進入最後階段，預計將推動全球靜脈注射免疫球蛋白市場的發展。例如，在印度，Bharat Biotech 正在進行研究，以產生單株抗體作為 COVID-19 的潛在治療方法。印度科學與工業研究理事會 (CSIR) 已核准該計劃作為其新千禧年印度技術領導策略的一部分。此外，COVID-19 為患有精神和神經病變的患者帶來了重大問題，因為他們更容易受到感染。例如，2021 年 4 月，領先的血漿衍生藥物供應商 Grifols 與 NIH 和 NIAID 合作參與了一項門診病人抗 SARS-CoV-2 高劑量靜脈注射免疫球蛋白的分析研究。預計這將在預測期內促進市場成長。

主要企業正在採用策略聯盟來保持競爭力。這些努力包括併購、聯盟和新產品開發。例如，Grifols 的 XEMBIFY 於 2022 年 3 月在歐洲核准，增加了新藥的機會。憑藉此歐洲核准，Grifols 擴大了其創新的歐洲 IG 產品組合，為患者和醫療保健專業人員提供了原發性和次發性免疫力缺乏的重要新治療方案。 2021年2月，輝瑞獲得美國FDA批准其靜脈注射免疫球蛋白PANZYGA的補充生技藥品核准申請(sBLA)，用於治療患有重度發炎性去髓鞘化多發性神經病變(CIDP)的成年患者。

靜脈注射免疫球蛋白市場報告重點

  • 低丙種球蛋白血症應用領域在 2024 年佔據第三大收益佔有率。這是由於意識層級的提高和疾病發病率的上升導致對治療低丙種球蛋白血症的免疫球蛋白替代療法的需求不斷增加。
  • 預計預測期內專業藥局將經歷顯著成長。醫院提供便利的居家護理，對許多患者來說是個有吸引力的選擇。這是因為醫院網路龐大，而且透過醫院藥局可以輕鬆獲得種類繁多的便利產品。此外，醫院為許多患者提供快速的報銷、治療和適當的護理，使得選擇醫院藥房的患者數量激增。
  • 由於專業藥房能夠實現居家治療，因此預計專業藥房分銷管道部分將在預測期內以豐厚的複合年成長率擴張。
  • 由於擁有完善的醫療保健體系、龐大的目標人口以及患者對血漿蛋白療法的高度認知，北美在 2024 年的銷售額中佔了 46.11% 的最大佔有率。
  • 亞太地區 IVIG 市場正在迅速擴張，這得益於免疫不全症盛行率的顯著上升，尤其是在中國、印度、日本和澳洲等國家。
  • 由於醫療設施的改善、醫療支出的增加以及公眾對免疫不全症的意識提高，預計印度、中國和南非等國家將在預測期內實現顯著成長。
  • 預計在預測期內，川崎病領域將成為市場上成長最快的領域。

目錄

第1章調查方法與範圍

第 2 章執行摘要

3. 靜脈注射免疫球蛋白市場變數、趨勢與範圍

  • 母市場展望
  • 補貼市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場問題分析
  • 靜脈注射免疫球蛋白分析工具
    • 波特的分析
    • PESTEL 分析

第 4 章靜脈免疫球蛋白市場的應用、估計與趨勢分析

  • 靜脈注射免疫球蛋白市場：應用細分儀表板
  • 靜脈注射免疫球蛋白市場：2024 年和 2030 年應用趨勢分析
  • 免疫不全症
  • CIDP
  • 低丙種球蛋白血症
  • 先天性愛滋病
  • 慢性淋巴性白血病
  • 重症肌無力
  • 多灶性運動神經病變
  • 免疫球蛋白
  • 川崎病
  • 格林-巴利綜合症
  • 其他

5. 靜脈注射免疫球蛋白市場按通路分類、估計和趨勢分析

  • 靜脈注射免疫球蛋白市場：通路細分儀表板
  • 靜脈注射免疫球蛋白市場：2024 年和 2030 年通路變化分析
  • 醫院藥房
  • 專業藥房
  • 其他

6. 靜脈注射免疫球蛋白市場區域分佈、預測及趨勢分析

  • 靜脈注射免疫球蛋白市場佔有率（按地區分類），2024 年和 2030 年，單位：百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 南非

第7章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 2024 年公司市場佔有率分析
  • 2024 年企業熱圖分析
  • 公司簡介
    • BIoTest AG.
    • Baxter.
    • Octapharma AG
    • LFB
    • Grifols SA
    • CSL.
    • China Biologics Products Inc.
    • Kedrion.
    • BDI Pharma Inc.
Product Code: 978-1-68038-800-8

Intravenous Immunoglobulin Market Growth & Trends:

The global intravenous immunoglobulin market size is estimated to reach USD 21.05 billion by 2030, expanding at a CAGR of 7.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of immunodeficiency diseases, coupled with the adoption of intravenous immunoglobulin (IVIG) therapies, is expected to fuel market growth over the forecast period. In addition, increasing off-label use of immunoglobulin and investments in the healthcare sector are factors propelling the market growth. Moreover, increasing incidences of bleeding disorders and the growing geriatric population are the factors contributing to the industry growth.

The rising incorporation of subcutaneous immunoglobulin in the treatment of primary immunodeficiency diseases as well as in replacement therapy is anticipated to provide a growth platform to the market in the next seven years. Moreover, the key market players are focusing on breakthrough product introductions to expand their global distribution network. For instance, Octapharma U.S. got FDA clearance in July 2021 for Octagam 10%, its first intravenous immunoglobulin recommended for the treatment of the immune-mediated inflammatory illness known as dermatomyositis in adults.

The COVID-19 pandemic, which is currently in its last stages, is expected to boost the worldwide market for intravenous immunoglobulin. In India, for instance, Bharat Biotech is conducting a study to create monoclonal antibodies as a potential COVID-19 treatment. The Council of Scientific and Industrial Research (CSIR) has approved the project as part of its New Millennium Indian Technology Leadership strategy. Moreover, COVID-19 has caused substantial issues for patients with mental and neurological disorders due to their increased susceptibility to infection. For instance, in April 2021, Grifols, a key provider of plasma-derived medicines, contributed to a research study in collaboration with both the NIH and NIAID, to analyze an intravenous anti-SARS-CoV-2 hyperimmune globulin among outpatients. This is expected to provide a boost to the market growth in the forecast period.

Key players are adopting strategic alliances to sustain the competition. These initiatives include mergers & acquisitions, collaborations, and new product developments. For instance, in March 2022, Grifols' XEMBIFY has been approved in Europe, increasing access to novel medicines. Grifols' clearance in Europe allows it to extend its breakthrough European IG product range and offer patients and healthcare professionals another crucial therapy solution for primary and secondary immunodeficiencies. In February 2021, Pfizer gained US FDA clearance for the supplemental Biologics License Application (sBLA) with PANZYGA, an intravenous immunoglobulin to cure adult patients with severe inflammatory demyelinating polyneuropathy (CIDP).

Intravenous Immunoglobulin Market Report Highlights:

  • The hypogammaglobulinemia application segment held the third-largest revenue share in 2024. This can be attributed to the increasing demand for immunoglobulin replacement therapies to treat hypogammaglobulinemia diseases, which is driven by rising awareness levels amongst patients and increasing incidences of the disease
  • Specialty pharmacy is expected to grow considerably over the forecast period. They offer the convenience of at-home treatment, making them an attractive option for many patients owing to the large network of hospitals and the convenient range of products that are easily accessible through hospital pharmacies. Furthermore, hospitals offer fast reimbursement, treatment, and proper care to a large number of patients, enabling a surge in the prevalence of patients selecting hospital pharmacie
  • The specialty pharmacy distribution channel segment is anticipated to expand at a lucrative CAGR during the forecast period as specialty pharmacies enable easy treatment at home
  • North America held the largest share of 46.11% in terms of revenue in 2024 due to the presence of a well-regulated healthcare system, the larger pool of target population, and high patient awareness pertinent to the plasma protein products
  • The IVIG market in Asia Pacific is expanding rapidly, driven by a significant increase in the incidence of immunodeficiency diseases, particularly in countries such as China, India, Japan, and Australia.
  • Countries such as India, China, and South Africa are expected to witness significant growth over the forecast period owing to improving healthcare facilities, rising healthcare expenditure, and growing public awareness regarding immune deficiency disorders
  • The Kawasaki disease segment is expected to exhibit the fastest growth in the market over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Intravenous Immunoglobulin (IVIG) Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising prevalence of immunodeficiency diseases
      • 3.3.1.2. Increasing adoption of immunoglobulin replacement therapy
      • 3.3.1.3. Rising geriatric population
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Cost intensive nature of immunoglobulin replacement therapy
      • 3.3.2.2. Stringent regulations pertaining to production and approvals
    • 3.3.3. Market Challenge Analysis
      • 3.3.3.1. Quality assurance and standardization-related challenges
      • 3.3.3.2. Limited scope for multiple evaluations
  • 3.4. Intravenous Immunoglobulin (IVIG) Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Intravenous Immunoglobulin (IVIG) Market: By Application Estimates & Trend Analysis

  • 4.1. Intravenous Immunoglobulin (IVIG) Market: Application Segment Dashboard
  • 4.2. Intravenous Immunoglobulin (IVIG) Market: By Application Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Immunodeficiency Diseases
    • 4.3.1. Immunodeficiency Diseases Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4. CIDP
    • 4.4.1. CIDP Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Hypogammaglobulinemia
    • 4.5.1. Hypogammaglobulinemia Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Congenital AIDS
    • 4.6.1. Congenital AIDS Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.7. Chronic Lymphocytic Leukemia
    • 4.7.1. Chronic Lymphocytic Leukemia Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.8. Myasthenia Gravis
    • 4.8.1. Myasthenia Gravis Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.9. Multifocal Motor Neuropathy
    • 4.9.1. Multifocal Motor Neuropathy Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.10. ITP
    • 4.10.1. ITP Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.11. Kawasaki Disease
    • 4.11.1. Kawasaki Disease Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.12. Guillain-Barre Syndrome
    • 4.12.1. Guillain-Barre Syndrome Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.13. Others
    • 4.13.1. Others Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Intravenous Immunoglobulin (IVIG) Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Intravenous Immunoglobulin (IVIG) Market: Distribution Channel Segment Dashboard
  • 5.2. Intravenous Immunoglobulin (IVIG) Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Hospital Pharmacies
    • 5.3.1. Hospital Pharmacies Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4. Specialty Pharmacies
    • 5.4.1. Specialty Pharmacies Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Intravenous Immunoglobulin (IVIG) Market: Regional Estimates & Trend Analysis

  • 6.1. Intravenous Immunoglobulin (IVIG) Market Share, By Region, 2024 & 2030, USD Million
  • 6.2. North America
    • 6.2.1. North America Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018- 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Norway
      • 6.3.8.1. Norway Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Sweden Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2017 - 2030 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. UAE
      • 6.6.3.1. UAE Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Kuwait
      • 6.6.4.1. Kuwait Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Africa
      • 6.6.5.1. South Africa Intravenous Immunoglobulin (IVIG) Market Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Company Heat Map Analysis, 2024
  • 7.5. Company Profiles
    • 7.5.1. Biotest AG.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Recent Developments/ Strategic Initiatives
    • 7.5.2. Baxter.
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Recent Developments/ Strategic Initiatives
    • 7.5.3. Octapharma AG
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Recent Developments/ Strategic Initiatives
    • 7.5.4. LFB
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Recent Developments/ Strategic Initiatives
    • 7.5.5. Grifols SA
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Recent Developments/ Strategic Initiatives
    • 7.5.6. CSL.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Recent Developments/ Strategic Initiatives
    • 7.5.7. China Biologics Products Inc.
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Recent Developments/ Strategic Initiatives
    • 7.5.8. Kedrion.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Recent Developments/ Strategic Initiatives
    • 7.5.9. BDI Pharma Inc.
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 4 Global Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 North America Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 7 North America Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 9 U.S. Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 Canada Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 11 Canada Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 13 Mexico Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 16 Europe Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Germany Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 18 Germany Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 U.K. Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 U.K. Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 France Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 22 France Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Italy Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 24 Italy Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Spain Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 26 Spain Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Denmark Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 28 Denmark Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Sweden Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 30 Sweden Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Norway Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 32 Norway Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 China Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 37 China Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Japan Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 39 Japan Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 India Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 41 India Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 South Korea Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 43 South Korea Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Australia Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 45 Australia Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Thailand Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 47 Thailand Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Latin America Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Latin America Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 50 Latin America Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Brazil Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 52 Brazil Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Argentina Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 54 Argentina Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market, by Country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 South Africa Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 59 South Africa Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 UAE Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 63 UAE Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Intravenous Immunoglobulin (IVIG) Market, by Application, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Intravenous Immunoglobulin (IVIG) Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & forecasting
  • Fig. 6 Market formulation & Validation
  • Fig. 7 Intravenous Immunoglobulin, Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five forces Analysis
  • Fig. 15 Global Intravenous Immunoglobulin Market: By Application Movement Analysis
  • Fig. 16 Global Intravenous Immunoglobulin Market, for Immunodeficiency Diseases, 2018 - 2030 (USD Million)
  • Fig. 17 Global Intravenous Immunoglobulin Market, for CIDP, 2018 - 2030 (USD Million)
  • Fig. 18 Global Intravenous Immunoglobulin Market, for Hypogammaglobulinemia, 2018 - 2030 (USD Million)
  • Fig. 19 Global Intravenous Immunoglobulin Market, for Congenital AIDS, 2018 - 2030 (USD Million)
  • Fig. 20 Global Intravenous Immunoglobulin Market, for Chronic Lymphocytic Leukemia, 2018 - 2030 (USD Million)
  • Fig. 21 Global Intravenous Immunoglobulin Market, for Myasthenia Gravis, 2018 - 2030 (USD Million)
  • Fig. 22 Global Intravenous Immunoglobulin Market, for Multifocal Motor Neuropathy, 2018 - 2030 (USD Million)
  • Fig. 23 Global Intravenous Immunoglobulin Market, for ITP, 2018 - 2030 (USD Million)
  • Fig. 24 Global Intravenous Immunoglobulin Market, for Kawasaki Disease, 2018 - 2030 (USD Million)
  • Fig. 25 Global Intravenous Immunoglobulin Market, for Guillain-Barre Syndrome, 2018 - 2030 (USD Million)
  • Fig. 26 Global Intravenous Immunoglobulin Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 27 Global Intravenous Immunoglobulin Market: Distribution Channel Movement Analysis
  • Fig. 28 Global Intravenous Immunoglobulin Market, for Hospital Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Global Intravenous Immunoglobulin Market, for Specialty Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 30 Global Intravenous Immunoglobulin Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 31 Regional Marketplace: Key Takeaways Intravenous Immunoglobulin Market, Region 2018 - 2030 (USD Million)
  • Fig. 32 Regional Outlook, 2022 & 2030 Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 33 Global Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 34 North America Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 35 US Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 40 UK Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 41 France Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 49 China Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 50 India Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 60 UAE Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
  • Fig. 62 Company/Competition Categorization
  • Fig. 63 Company Market Share Analysis, 2024
  • Fig. 64 Company Market Position Analysis, 2024
  • Fig. 65 Strategy Mapping